1. Draw 0.5 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake vigorously).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe.

Selank is a synthetic analog of the immunomodulatory peptide tuftsin, consisting of the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. In Russian clinical trials for anxiety disorders and neurasthenia, intranasal Selank produced anxiolytic effects comparable to benzodiazepines while also providing anti-asthenic (energy-boosting) benefits without sedative side effects or dependence potential. Preclinical studies in primates demonstrated that intranasal Selank eliminated fear and anxiety behaviors with long-term stabilizing effects on neurobehavior. Rodent studies confirmed robust anxiolytic efficacy comparable to classical tranquilizers. While most published human data utilized intranasal dosing, subcutaneous administration has shown effectiveness in research settings with consistent absorption and ease of dose measurement.

• Produces anxiolytic effects comparable to benzodiazepines in human clinical trials without sedation or
  dependence risk.
• Provides anti-asthenic (energy-boosting) benefits alongside anxiety reduction.
• Induces lasting neurobehavioral changes; primate studies showed elimination of fear/anxiety behaviors
  with long-term stabilizing effects.
• Generally well tolerated in clinical studies; a 14-day continuous course was well-tolerated and effective in
  human trials.
• Occasional mild injection-site reactions (redness, minor irritation) may occur with subcutaneous
  administration.
• Lacks sedative side effects typical of classical anxiolytics, allowing for daytime use without impairment.